» Articles » PMID: 37124861

Comparison Among Plaque Assay, Tissue Culture Infectious Dose (TCID) and Real-time RT-PCR for SARS-CoV-2 Variants Quantification

Abstract

Background And Objectives: SARS-CoV-2 variants of concern (VOC) and interest (VOI) pose a significant threat to public health because the rapid change in the SARS-CoV-2 genome can alter viral phenotypes such as virulence, transmissibility and the ability to evade the host response. Hence, SARS-CoV-2 quantification techniques are essential for timely diagnosis and follow-up. Besides, they are vital to understanding viral pathogenesis, antiviral evaluation, and vaccine development.

Materials And Methods: Five isolates of SARS-CoV-2: D614G strain (B.1), three VOC (Alpha, Gamma and Delta), and one VOI (Mu) were used to compare three techniques for viral quantification, plaque assay, median tissue culture infectious dose (TCID) and real-time RT-PCR.

Results: Plaque assay showed viral titers between 0.15 ± 0.01×10 and 1.95 ± 0.09×10 PFU/mL while viral titer by TCID assay was between 0.71 ± 0.01×10 to 4.94 ± 0.80×10 TCID/mL for the five SARS-CoV-2 isolates. The PFU/mL titer obtained by plaque and the calculated from TCID assays differed by 0.61 log10, 0.59 log10, 0.59 log10 and 0.96 log10 for Alfa, Gamma, Delta, and Mu variants (p≤0.0007), respectively. No differences were observed for the D614G strain. Real-time PCR assay exhibited titers ranging from 0.39 ± 0.001×10 to 3.38 ± 0.04×10 RNA copies/μL for all variants. The relation between PFU/mL and RNA copies/mL was 1:29800 for D614G strain, 1:11700 for Alpha, 1:8930 for Gamma, 1:12500 for Delta, and 1:2950 for Mu.

Conclusion: TCID assay was comparable to plaque assay for D614G but not for others SARS-CoV-2 variants. Our data demonstrated a correlation among PFU/mL and E gene RNA copies/μL, units of measure commonly used to quantify the viral load in diagnostic and research fields. The results suggest that the proportion of infectious virions changes depending on the SARS-CoV-2 variant, being Mu, the variant reaching a higher viral titer with fewer viral copies.

Citing Articles

A systems biology approach unveils different gene expression control mechanisms governing the immune response genetic program in peripheral blood mononuclear cells exposed to SARS-CoV-2.

Marin D, Fernandez G, Hernandez J, Taborda N PLoS One. 2024; 19(12):e0314754.

PMID: 39637135 PMC: 11620636. DOI: 10.1371/journal.pone.0314754.


Establishment of a novel cell line for producing replication-competent adenovirus-free adenoviruses.

Han E, Kim Y BMC Biotechnol. 2024; 24(1):67.

PMID: 39334326 PMC: 11429178. DOI: 10.1186/s12896-024-00894-x.


High-Throughput Determination of Infectious Virus Titers by Kinetic Measurement of Infection-Induced Changes in Cell Morphology.

Hotter D, Kunzelmann M, Kiefer F, Leukhardt C, Fackler C, Jager S Int J Mol Sci. 2024; 25(15).

PMID: 39125646 PMC: 11311753. DOI: 10.3390/ijms25158076.


In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach.

Zapata-Cardona M, Florez-Alvarez L, Guerra-Sandoval A, Chvatal-Medina M, Guerra-Almonacid C, Hincapie-Garcia J AIMS Microbiol. 2023; 9(1):20-40.

PMID: 36891537 PMC: 9988408. DOI: 10.3934/microbiol.2023002.

References
1.
Corman V, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu D . Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020; 25(3). PMC: 6988269. DOI: 10.2807/1560-7917.ES.2020.25.3.2000045. View

2.
Khateeb J, Li Y, Zhang H . Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care. 2021; 25(1):244. PMC: 8274962. DOI: 10.1186/s13054-021-03662-x. View

3.
Jureka A, Silvas J, Basler C . Propagation, Inactivation, and Safety Testing of SARS-CoV-2. Viruses. 2020; 12(6). PMC: 7354523. DOI: 10.3390/v12060622. View

4.
Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah M . Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021; 596(7871):276-280. DOI: 10.1038/s41586-021-03777-9. View

5.
Shurtleff A, Biggins J, Keeney A, Zumbrun E, Bloomfield H, Kuehne A . Standardization of the filovirus plaque assay for use in preclinical studies. Viruses. 2012; 4(12):3511-30. PMC: 3528277. DOI: 10.3390/v4123511. View